Department of Medical Biology ahmed.bargheet@uit.no +4777646836 Tromsø MH L9.229

Bargheet, Ahmed

Doctoral research fellow

Job description

I am a link in a chain that focuses on fighting antibiotic resistance. So, without exaggeration, we are working for saving the world from AMR danger that is projected to kill 10 million people by 2050.

Current position

  • Ph.D. fellow, Department of Medical Biology, The Arctic University of Norway
  • Member of Research Group for Host-Microbe interaction (HMI)
  • Member of Pediatric Research Group 

My main work is bioinformatics, however, because of my background, I am fairly competent in the following skills:

  • Linux system
  • High-performance computing (HPC) system
  • R and Shiny R
  • Metagenomic data analysis
  • Functional metagenomics
  • Nucleic acid extraction
  • PCR and RT-PCR
  • Gel electrophoresis
  • Western Blotting
  • Flow Cytometry


  • MSc Applied Biotechnology, Inland Norway University of Applied Sciences
  • Bc Pharmacy, Al-Azhar University in Cairo



Research interests

My previous work

 I worked on the evaluation of the impact of long-term amoxicillin administration on the human resistome using functional metagenomics

Five novel genes were identified at which one of them could resist the PenicillinG at a MIC higher than the breakpoint reported by EUCAST by 300 times.

Current work

Funded by Helse Nord RHF

  • First project (PINGU)

This is an observational, longitudinal study that included 31 probiotic-supplemented extremely preterm infants, 35 very preterm infants not given probiotics, and 10 healthy full-term control infants. This study will identify the impact of probiotics and antibiotic therapy on infants gut microbiota, resistome, and mobilome.

  • Second project (ProRIDE)

This is a randomized clinical trial co-led by the Pediatric Research group in Tromsø (UiT / UNN), which investigates the impact of probiotic therapy in Tanzanian infants and its potential to prevent infections by ESBL-producing Enterobacterales.

  • Third project (IMPALE) 

This is a pilot study of newborns with suspected signs of infection during the 1st week of life leading to antibiotic therapy. The purpose of the study is to report changes in fecal microbial composition in relation to antibiotic usage and integrate the result with a metabolomics study.